Politics and expertise: How to use science in a democratic society
By Zeynep Pamuk,
LSE European Politics and Policy Blog
| 03. 30. 2022
The Covid-19 pandemic has underlined the importance of scientific advice to modern policymaking. But how can the use of expertise in politics be aligned with the needs and values of the public? Drawing on a recent book, Zeynep Pamuk sets out a new model for the relationship between science and democracy.
The Covid-19 pandemic has put scientific advisory bodies under the spotlight as rarely before. The question of how scientific advisers should communicate their guidance in the face of wavering trust in science and scientists has subsequently received much scholarly and public attention over the past two years. But while the focus on scientific advice is certainly important, there is a limit to how far the problems in the relationship between science and politics can be fixed at the advisory stage.
After all, advisers are constrained by the knowledge available to them. Their recommendations depend on earlier decisions about which scientific questions should be pursued and how. To improve the relationship between science and democracy and ensure more effective responses to issues such as pandemics and climate change, we must...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...